Search results for “Immunomodulatory

About 4 results in articles

Open Access Pub publishes peer-reviewed, free-to-read open-access articles. Showing articles matching Immunomodulatory — open any to read the full text, or download the PDF or XML.

4 articles

Evaluation of Immunomodulatory Effect of a Novel Test Formulation in D-Galactose-Induced Aging Dysfunction in Sprague Dawley Rats

Jul 2021 DOI 10.14302/issn.2474-7785.jarh-21-3850
Jana SnehasisCorresponding author Trivedi Science Research Laboratory Pvt. Ltd., Thane (W), Maharashtra, India.

The aim of the study was to evaluate the immunomodulatory activity of the Biofield Treated/Blessed proprietary test formulation consisting of essential ingredients viz. minerals (zinc, magnesium, iron, and copper) and vitamins (B6, B12, and D3) in male Sprague Dawley rats. Each ingredient of the test formulation was divided into two parts. One part was denoted as the control without any Biofield Energy Healing Treatment/Blessing, while the other part was defined as the Biofield Energy Treated/Blessed sample, which received the Biofield Energy Healing Treatment/Blessing by a renowned Biofield Energy Healer, Mr. Mahendra Kumar Trivedi remotely. Additionally, three group of animals were also received Biofield Energy Treatment per se (at day -15) under similar conditions. The parameters were assessed such as immune biomarkers (IgM, IgG, IgA, IgE, CD4+, CD8+, and CD28+), biochemistry and hematology and histopathology. The experimental results showed IgG level was significantly increased by 10.70% and 8.03% in the G6 (Biofield Energy Treatment per se at day -15) and G8 (Biofield Treatment per se to animals plus Biofield Treated test formulation from day -15) groups, respectively as compared with untreated test formulation (G4). Additionally, CD8+ count was significantly increased by 20.67% in the G8 group, while CD28+ count was significantly increased by 11.70%, 8.32%, and 9.82% in the G7 (Biofield Energy Treated test formulation at day -15), G8, and G9 (Biofield Treatment per se (day -15) to animals plus untreated test formulation) groups, respectively after Biofield Energy Treatment to the animals as compared with the untreated test formulation. In hematological analysis, platelet count was increased in the G5, G6, G7, G8, and G9 groups by 40.69%, 27.95%, 26.67%, 38.58%, and 28.28%, respectively compared with the disease control (G2) group. Biochemical parameters showed significant decrease in the level of creatinine by 32.14% in the G9 group as compared with the G2 group. Further, animal body weight, feed intake, relative organ weight, and histopathological findings of all the tested groups did not show any abnormal findings with respect to the safe and non-toxic treatment strategies. Overall, the experimental data concluded that the Biofield Energy Treated/Blessed test formulation showed considerable improved cellular and humoral immune response as compared with the untreated test formulation. Thus, the Trivedi Effect®-Biofield Energy Healing Treatment per se and the test formulation has the significant capacity for immunomodulatory effect, stress management and anti-aging by improving overall health.  

Ophthalmic Science Open Access

Early Versus Late Immunomodulatory Therapy in Vogt-Koyanagi-Harada disease

Aug 2017 DOI 10.14302/issn.2470-0436.jos-17-1666
P. Storey PhilipCorresponding author USC Roski Eye Institute, University of Southern California

Purpose: To evaluate early versus late immunomodulatory therapy (IMT) for patients following initial diagnosis of Vogt-Koyanagi-Harada (VKH) disease. Methods: Retrospective review including all VKH patients seen 5/1/2014 to 4/1/2016 at LAC+USC. Early IMT was defined as starting an immunomodulatory agent within 3 months of corticosteroid initiation. Results: Twenty-seven patients were included, of whom 15 received early IMT and 8 received late IMT. Early IMT patients trended toward greater improvement in vision compared to late IMT (logMAR 0.59 vs. 0.11; p=0.14) with no differences in ocular complications including ocular hypertension (p=0.53) and cataract (p=1.0). Patients receiving early IMT averaged 0.93 recurrences versus 2.13 recurrences for late IMT (p=0.092). Of patients successfully taper off oral corticosteroids, the early IMT group was tapered in an average of 8.3 months versus 19.8 months for late IMT (p=0.0019). Conclusions: Early IMT in VKH may allow for shorter duration of corticosteroids with similar visual outcomes, ocular complications, and disease recurrences.

Lenalidomide-Induced High Grade Fever in a Patient with Multiple Myeloma: A Case Report

Mar 2019 DOI 10.14302/issn.2641-5518.jcci-19-2664
ElGohary GhadaCorresponding author Department of Adult Hematology/Internal Medicine, Ain Shams University Hospitals, College Of Medicine, Cairo, Egypt

Lenalidomide is a second generation immunomodulatory agent and a potent analogue of thalidomide that is FDA approved mainly for the treatment of multiple myeloma (MM) and transfusion-dependent anemia due to low or intermediate-1- risk myelodysplastic syndromes (MDS) associated with 5q deletion among other indications. Through its action on the immune system, lenalidomide alters the production of different cytokines ultimately resulting in immune activation against tumors. This immune activation may lead to collateral immune toxicities like fever, angioedema, Stevens-Johnson syndrome, tumor flare and others. Here we report a case of lenalidomide-induced high grade fever in a patient with MM and we summarize the literature about the physiology of such reaction and how to mitigate this adverse event.

Cervical Cancer Open Access

Gene-Eden-VIR: A Potential Natural Treatment for Cervical Cancer

Mar 2016 DOI 10.14302/issn.2997-2108.jcc-15-856
Polansky HananCorresponding author The Center for the Biology of Chronic Disease (CBCD), Rochester, USA.

This paper explores the potential of Gene‑Eden‑VIR as an adjunctive approach for cervical cancer prevention or management. The discussion reviews proposed antiviral and immunomodulatory mechanisms, existing evidence, and safety considerations. The authors call for controlled trials to clarify efficacy and appropriate clinical use.

Frequently asked questions

Are these articles peer-reviewed?
Yes. Articles published at Open Access Pub go through single-blind peer review (double-blind on request) under an editorial board before publication.
Are the articles free to read?
Yes. Every article is open access — read the full text online for free and download the PDF or XML, with no paywall or subscription.
How do I cite an article?
Use the DOI shown on each result and on the article page; it is the permanent, citable link to the article.
How do I read or download an article?
Click "Read full text" to open the article HTML, or use the PDF / XML buttons on each card to download it.